Table 5.

Differences in severe maternal morbidity compared between the first and second half of the study period

Outcome	First half of study period (n=10,545)	Second half of study period (n=11,893)	P value
Composite severe maternal morbidity,a n (%)	703 (6.7)	882 (7.4)	.03
Severe obstetrical hemorrhage,b n (%)	53 (0.5)	82 (0.7)	.07
Sepsis, n (%)	19 (0.2)	35 (0.3)	.08
Hypertension or neurologic morbidity,c n (%)	550 (5.2)	688 (5.8)	.06
Pulmonary morbidity,d n (%)	73 (0.7)	69 (0.6)	.3
Cardiac morbidity,e n (%)	8 (0.1)	8 (0.1)	.8
ICU admission, n (%)	65 (0.6)	66 (0.6)	.5

HELLP, hemolysis, elevated liver enzymes, low platelet count; ICU, intensive care unit.

^aIncludes patients with at least 1 of the following complications during pregnancy: obstetrical hemorrhage requiring transfusion of ≥4 packed red blood cells, uterine artery embolization, peripartum hysterectomy, eclampsia, stroke, severe hypertension requiring antihypertensive therapy, HELLP syndrome, sepsis, acute respiratory distress syndrome, pulmonary edema, mechanical ventilation, venous thromboembolism, myocardial infarction, peripartum cardiomyopathy, or ICU admission

^bIncludes patients with at least 1 of the following: obstetrical hemorrhage requiring transfusion of ≥4 packed red blood cells, uterine artery embolization, or peripartum hysterectomy

^cIncludes patients with at least 1 of the following: eclampsia, stroke, severe hypertension requiring antihypertensive therapy, or HELLP syndrome

^dIncludes patients with at least 1 of the following: acute respiratory distress syndrome, pulmonary edema, mechanical ventilation, or venous thromboembolism

^eIncludes patients with at least 1 of the following: myocardial infarction, peripartum cardiomyopathy.

Gulerson. Severe maternal morbidity associated with COVID-19. Am J Obstet Gynecol MFM 2022.